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Abstract
A new commercial anti-Japanese encephalitis virus IgM and IgG indirect immunofluorescence test (IIFT) was evaluated for
the detection of the humoral immune response after Japanese encephalitis vaccination. The IgM IIFT was compared to two
IgM capture ELISAs and the IgG IIFT was analysed in comparison to a plaque reduction neutralization test (PRNT50) and an
IgG ELISA. Moreover, the course of the immune reaction after vaccination with an inactivated JEV vaccine was examined. For
the present study 300 serum samples from different blood withdrawals from 100 persons vaccinated against Japanese
encephalitis were used. For the IgM evaluation, altogether 78 PRNT50 positive samples taken 7 to 56 days after vaccination
and 78 PRNT50 negative sera were analyzed with the Euroimmun anti-JEV IgM IIFT, the Panbio Japanese Encephalitis –
Dengue IgM Combo ELISA and the InBios JE Detect IgM capture ELISA. For the IgG evaluation, 100 sera taken 56 days after
vaccination and 100 corresponding sera taken before vaccination were tested in the PRNT50, the Euroimmun anti-JEV IgG
IIFT, and the InBios JE Detect IgG ELISA. The Euroimmun IgM IIFT showed in comparison to the Panbio ELISA a specificity of
95% and a sensitivity of 86%. With respect to the InBios ELISA, the values were 100% and 83.9%, respectively. The analysis of
the Euroimmun IgG IIFT performance and the PRNT50 results demonstrated a specificity of 100% and a sensitivity of 93.8%,
whereas it was not possible to detect more than 6.6% of the PRNT50 positive sera as positive with the InBios JE Detect IgG
ELISA. Thus, the IIFT is a valuable alternative to the established methods in detecting anti-JEV antibodies after vaccination in
travellers and it might prove useful for the diagnosis of acutely infected persons.
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Introduction
Japanese encephalitis virus (JEV), a mosquito-borne pathogen of
the genus Flavivirus, family Flaviviridae, is the main cause of viral
encephalitis in Asia. Three billion people live in the endemic areas
and at least 50,000 clinical Japanese encephalitis (JE) cases occur
each year, which are a great burden to the affected populations
[1,2]. JEV is widespread throughout Asia up to the northern tip of
Australia [3,4] and is considered as an emerging or re-emerging
virus [5]. It is transmitted by bloodsucking Culex mosquitoes -
predominantly Culex tritaeniorhynchus. Most cases occur in rural
areas, but transmission is also found in peri-urban and urban
centres [6]. The disease can only be treated symptomatically but
different vaccines are available for preventing it.
A mouse brain derived and formalin-inactivated JE vaccine
(strains Nakayama and Beijing-1), produced by Asian companies,
was the predominantly used vaccine for a long time. Only one of
these vaccine products (JE-VAXH) was licensed in some non-
endemic countries. In recent years Chinese manufacturers have
developed a live attenuated and an inactivated vaccine, produced
principally on primary hamster kidney cells, and of these the
Chinese live attenuated SA14-14-2 vaccine has become widely
used in endemic countries [7]. Additionally, other JE vaccines are
under development or in the licensing process, e.g. a chimeric live
attenuated vaccine based on the yellow fever virus 17D backbone.
In this study the formalin-inactivated SA14-14-2 vaccine strain,
cultivated on Vero cells, was used, which was recently licensed in
the USA, Europe and Australia [2,8,9].
Besides the personal protection against mosquito bites, the CDC
recommends administration of the JE vaccine to native and
expatriate residents of endemic areas, and to travellers staying a
month or longer in endemic, especially rural areas during the
transmission season [10]. But the risk of JEV infection of persons
from non-endemic regions travelling to endemic regions varies
with duration, season, place and purpose of the stay, and should be
assessed for each traveller individually even if only staying for a
short time [11].
The clinical presentation of a JEV infection varies from non-
specific febrile illness to severe meningoencephalitis, the main
clinical manifestation. Only 1 in 250 to 500 infections is
symptomatic. After the incubation period of 4 to 14 days the
patients mostly show a rapid onset of fever, headache and
gastrointestinal symptoms. Neurological symptoms develop subse-
quently, with a spectrum ranging from neck stiffness, stupor and
impaired consciousness to seizures, parkinsonian movement
disorders, convulsions, flaccid paralysis and coma. The mortality
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significant long-term neuropsychiatric sequelae [6,12,13,14,15].
The clinical picture of JE resembles the picture of acute
encephalitis syndromes of other aetiologies and cannot be
differentiated accurately [16]. The confirmatory diagnosis there-
fore requires antigen or antibody determination. Cultivation of
JEV from blood and cerebrospinal fluid (CSF) is rarely positive as
the viraemic period lasts only a few days [2,12], thus diagnostics
rely mostly on serological assays. The flavivirus group shows
intense cross-reactivity which is highest on the IgG level. However
IgM is relatively specific for the infecting virus [17,18]. IgM is
detectable in CSF and blood from almost all patients within 7 days
after onset of disease [2].
For JE diagnostics ‘‘in-house’’ assays and commercial IgM
capture ELISAs are used most commonly. Recently, a commercial
indirect immunofluorescence test (IIFT) has become available.
The method provides the opportunity to combine different
substrates in form of an IIFT mosaic or profile in order to test
for other pathogens relevant for differential diagnosis as well as to
distinguish cross-reactive antibodies.
The aim of this study was to compare the performance of this
new commercially available IIFT with other established commer-
cial ELISAs and the ‘‘gold standard’’ in flavivirus diagnostics, the
plaque reduction neutralization test (PRNT) in detecting the
humoral immune response after immunisation with JE inactivated
vaccine. Moreover, the course of specific antibodies after JE
vaccination was determined using this new assay.
Materials and Methods
Sera panels
For this present retrospective study a serum collection was
examined which was derived from a randomized controlled
vaccination study performed by Intercell Biomedical Ltd., Living-
ston, UK. All details regarding the design of the vaccination study
have been published previously [8,19,20]. Previous Japanese
encephalitis or yellow fever vaccination was an exclusion criterion
for the participants. The sera were obtained from 100 persons
immunized with JEV vaccine IC51 (IXIAROH) on day 0 and day
28.Theserawerecollectedatfivedifferentpointsintime:day0(V0),
day 7 (V2), day 28 (V3), day 35 (V4) and day 56 (V5). They were
shipped on dry ice and stored at 220uC until use. Altogether 300
different sera were chosen for the present study as described below:
The samples from V5 (n=100) were analyzed for IgG with the
Euroimmun anti-JEV IgG IIFT and with the InBios JE Detect
IgG ELISA. For IgM altogether 78 samples from V2, V3, V4 and
V5 were analyzed with the Euroimmun anti-JEV IgM IIFT, with
the Panbio Japanese Encephalitis - Dengue IgM Combo ELISA
and with the InBios JE Detect IgM capture ELISA.
As negative controls for the anti-JEV IgM and IgG IIFT the
corresponding samples from V0 were incubated (IgM n=49, IgG
n=100). For IgM an additional 29 samples that had been tested
negative in PRNT50 were used as negative controls.
Blood donors from northern Germany were used to determine
the JEV antibody prevalence in the population detectable with the
Euroimmun anti-JEV IIFT. Two hundred IgM samples and 197
IgG samples from blood donors were assessed.
A panel of 20 JEV IgG IIFT positive sera from V5 and 10 JEV
IgM IIFT positive sera from V3 and V4 was tested with the
Flavivirus Profile 2, which allowed the cross-reactivity of anti-JEV
antibodies with other flavivirus IIFT substrates to be assessed.
In order to determine the possibility of excluding cross-reactivity
of anti-dengue positive sera in the JEV assays, a panel of 15 dengue
virus (DENV) IgM positive sera was tested with the Euroimmun
Flavivirus Profile 2 and a panel of ten dengue virus (DENV) IgM
positive sera was tested in the Panbio and Inbios IgM ELISA.
Additionally 20 DENV IgG positive sera were assessed in the
Flavivirus Profile 2 and InBios JE Detect IgG ELISA.
The course of the IgM and IgG response after JE vaccination
was analysed in all vaccinees, therefore all PRNT50 positive and
selected PRNT50 negative samples were assessed in IgM and IgG
IIFT. Six representative courses were chosen and used to present
the data in this study.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Ethics Committee of the Medical Association of Hamburg, the
Research Ethics Committee of Northern Ireland and the Ethics
Committee of the Charite ´, Berlin. Written informed consent was
obtained from all participants and all samples were analyzed
anonymously.
Serological tests
The PRNT50 was performed by the Intercell AG using a
modification of the method described by Sukhavachana et al. The
PRNT assay was carried out in a 24 well format. Briefly, serial 4-
fold dilutions of heat-inactivated serum were incubated in a
reaction volume of 1.2 mL for 1 h at 35uC with the JEV strain
SA14-14-2. 250 ml of these virus dilutions were plated in triplicate
onto monolayers of Vero cells, leading to 40–80 plaque forming
units/well. A methylcellulose overlay was used to restrict virus
spread. After 5 days of incubation at 35uC, the viral plaques were
fixed, stained with crystal violet, and automatically counted
(ProtoCOL HR Colony Counter, Synbiosis, Cambridge, UK).
PRNT50 titres (the serum dilution giving a 50% plaque reduction
compared to plaque formation in virus-only controls) were
calculated using a linear regression (probit) analysis program.
PRNT50 titres of$1:10 were rated as positive.
The commercial IIFT was produced at EUROIMMUN
Medizinische Labordiagnostika AG, Lu ¨beck, Germany, using Vero
E6 cells infected with a strain originating form the JEV Nakayama
strain (Genebank accession no. EF571853). The infected cells were
Author Summary
Japanese encephalitis, caused by the Japanese encepha-
litis virus, is the most prominent viral encephalitis in Asia.
Three billion people live in endemic areas and at least
50,000 clinical cases occur each year, although reliable
vaccines are available. Concerning the burden caused by
this disease, more should be done to prevent it. Good and
reliable diagnostics are one of the prerequisites for an
effective fight against the virus, but it is nearly impossible
to produce and evaluate an in-house assay according to
high standard quality criteria as done for commercial tests.
Only a few commercial assays are available and the
thorough evaluation of these assays is of great importance
for diagnostic laboratories. The sensitivity and specificity
are statistical measures to assess the performance of a
diagnostic assay. In this study the Euroimmun IgM indirect
immunofluorescence test (IIFT) was compared to the
Panbio and InBios IgM ELISAs. It showed a specificity of
95% and 100%, and a sensitivity of 86% and 93.8%,
respectively. The specificity of the IgG IIFT in comparison
to PRNT50 was 100% and the sensitivity was 93.8%.
Overall, the IIFT showed a comparable performance and
could be used as an alternative to the established assays.
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irradiation.Incontrasttoconventionalproduction methodsthe cells
were grown initially on thin glass slides, which were cut into
millimetre-sized fragments (biochips). The biochips were glued onto
the reaction fields of microscope slides, offering the possibility to
supplement the reaction fields with further biochip substrates. The
JEV IIFT assembles one biochip of infected and one of non-infected
Vero E6 cells in each reaction field.
For evaluation of the anti-JEV IIFT we examined IgM and IgG
antibodies in the serum panels using the Titerplane technique as
described in the instruction manual. For IgM detection, IgG and
rheumatic factors were pre-absorbed with the Eurosorb reagent
(EUROIMMUN Medizinische Labordiagnostika AG, Lu ¨beck,
Germany). Samples were diluted 1:10, 1:100 and 1:1000. 25 mLo f
the dilutions were applied to the reaction fields of a reagent tray.
The slides were then placed upside down into the recesses of the
reagent tray, allowing all biochips to come into contact with the
drops and the reactions to commence simultaneously under
identical conditions without the need of a humid chamber.
The cells were incubated for 30 min at room temperature with
the serum dilutions. After a washing step with PBS/Tween buffer,
either fluorescein isothiocyanat-labeled anti-human-IgG or -IgM
was added. Finally, the results were evaluated by fluorescence
microscopy with a 200-fold magnification using a 450–490 nm
excitation filter and a 515 nm blocking filter, without prior
knowledge of the precharacterization of the sera in PRNT50.
According to the Euroimmun standard procedure, the fluores-
cence intensity was rated in levels from 0 (no fluorescence) to 5
(very strong fluorescence) and titres were determined as follows: In
the 1:10 dilution, for example, level 1 was rated as 1:10, level 2 as
1:32, level 3 as 1:100 and level 4 and 5 were rated as more than
1:100. Titres of $1:10 were considered positive.
The Flavivirus Profile 2 (EUROIMMUN Medizinische Labor-
diagnostika AG, Lu ¨beck, Germany) was produced using the same
method as described for the anti-JEV IIFT. The test combines eight
different flavivirus substrates. Five reactionfieldsin the upper rowof
a 10-field slide were equipped with four different biochips each,
namely with tick-borne encephalitis, West Nile, Japanese enceph-
alitis and yellow fever virus infected cells. Each of the five reaction
fields in the bottom row was supplemented with four different
biochips containing cells infected with one of the four dengue virus
serotypes. Each serum dilution was incubated on these two different
reaction fields and evaluated as described above for the anti-JEV
IIFT. The assay can be used to determine the predominant
flavivirus antibody response and presumptive infection.
The Panbio Japanese Encephalitis - Dengue IgM Combo
ELISA (Panbio Diagnostics, Brisbane, Australia) is based on the
IgM capture format with insect cell expressed and immunopurified
JEV and dengue 1–4 antigens. The assay was performed as
advised by the manufacturer. 100 mL of the 1:100 diluted samples
were incubated for 1 h at 37uC and after six washing steps 100 mL
horseradish peroxidase conjugated monoclonal antibody/antigen
complexes were incubated for 1 h at 37uC. The reaction was
detected by TMB and read at 450 nm. Panbio Units were
calculated as described in the manual and a JE/dengue ratio of the
Panbio Units was determined. According to the instruction Panbio
Unit .11 are positive and,9 are negative. Panbio Units between
9 and 11 were rated as equivocal and were not considered in the
evaluation. This ratio gives presumptive information if the patient
is infected either by JEV or dengue virus. A JE/dengue ratio of $1
indicates a presumptive infection with JEV and a ratio of ,1
indicates a presumptive infection with DENV.
The InBios JE Detect IgG ELISA and IgM capture ELISA
(InBios International Inc., Seattle, Washington, USA) were also
performed as described in the manual. Both assays rely on the
usage of the JE recombinant antigen (JERA), a serological marker
which consists of different parts of JEV antigens. All incubation
steps were performed for 1 h at 37uC. For the detection step TMB
substrate was used, which was measured at 450 nm. For the IgG
assay the wells were either precoated with the JERA or with a
normal cell antigen (NCA) as a control. 50 mL of the 1:300 diluted
sera were applied to each well.
In the IgM-capture ELISA 50 mL of the 1:100 diluted sera were
used in each well.ThewellswereprecoatedwithantiIgMantibodies.
In a second step either JERA or NCA were added and detected with
a JERA specific horseradish peroxidase labelled antibody.
Immune status ratio (ISR) was calculated by dividing the JERA
OD with the NCA OD. IgM ISR values ,6 are negative and
.10.0 are positive whereas ratios between 6 and 10 are equivocal
and were taken out of the evaluation. For the IgG ELISA ISR
results .5.0 are rated as positive, values between 2.0 and 5.0 are
equivocal and values ,2 are negative.
The evaluation data of the Panbio Japanese Encephalitis -
Dengue IgM Combo ELISA and the InBios JE Detect IgM
capture ELISA with sera from infected persons have been
published previously [21,22].
All sera were blinded before being tested in IIFT and ELISA
and the testing was performed by an experienced technician using
the manufacturer’s manual. Calculation of 95% confidence
intervals (95% CI) was done using the Wilson method [23].
Results
IgM assay evaluation
For the IgM IIFT evaluation 78 PRNT50 positive samples (V2,
V3, V4 or V5) were tested in the IgM IIFT, the Panbio IgM
ELISA and the InBios IgM ELISA (Table 1). A negative cohort of
78 PRNT50 negative samples was used, which were all negative in
the IgM IIFT (Table 1).
In the Panbio IgM ELISA five of the 78 PRNT50 positive
samples (6.4%)wererated equivocalandweretherefore takenoutof
the evaluation. The equivocal samples had a geometric mean of the
PRNT50 values of 1:455. 61 of the 73 remaining samples showed
concordant results in IIFT and ELISA (43 positive, 18 negative)
whereas 12 samples differed. Five of these 12 samples showed false
positive results in comparison to the Panbio ELISA, with low IIFT
valuesfrom 1:10to1:32,andsevensampleswerefalsenegative.The
Panbio Units of these seven samples ranged from 13.8 to 24.9.
The geometric mean of the PRNT50 values for the 43 positive
samples was 1:535, for the 18 negative samples 1:109, for the five
samples positive in IIFT and negative in ELISA 1:240 and for the
seven samples negative in IIFT and positive in ELISA it was 1:457.
Compared to the Panbio IgM ELISA the IgM IIFT showed
altogether a specificity of 95% (95% CI 88.9–97.9%) and a
sensitivity of 86% (95% CI 73.8–93.1%) with a positive predictive
value of 89.6% (95% CI 77.8–95.5%) and a negative predictive
value of 93.2% (95% CI 86.6–96.7%) (Table 2).
In the InBios IgM ELISA eight of the 78 PRNT positive
samples (10.3%) could not be diagnosed due to an equivocal result
and were not considered in the evaluation. The equivocal samples
showed a geometric mean of the PRNT values of 1:212. Only one
sample was equivocal in both IgM ELISAs. 61 samples were
concordant (47 positive, 14 negative) between the ELISA and the
IIFT, whereas nine ELISA positive samples were negative in the
IIFT with ISR values between 10.6 and 30.1.
The geometric mean of the PRNT50 values for the 47 positive
samples was 1:503, for the 14 negative samples 1:108 and for the
nine samples negative in IIFT and positive in ELISA it was 1:433.
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ELISA demonstrated a specificity of 100% (95% CI 96–100%), a
sensitivity of 83.9% (95% CI 72.2–91.3%), a positive predictive
value of 100% (95% CI 92.4–100%) and a negative predictive
value of 91.1% (95% CI 83.9–95.2%) (Table 3).
Altogether six samples, positive with both ELISAs did not reveal
a positive result in IIFT. Differences in the determination of the
specificity were found between both IgM IIFT evaluations. Five
samples were negative in the Panbio IgM ELISA, but positive in
InBios IgM ELISA and IgM IIFT.
The comparison of the results of both ELISAs and the IIFT is
demonstrated in the graphical plot (Fig. 1). The relation between
the results is displayed by the increase of the trend lines. In
addition, in figure 2 the OD values of both IgM ELISAs are
compared to the corresponding PRNT50 results.
Additionally, the results of the PRNT50 were compared to the
results of the IgM IIFT and to both IgM-capture ELISAs. In the
Panbio IgM ELISA 64%, in the InBios IgM ELISA 72% and in
the IgM IIFT 65% of the 78 PRNT50 positive sera were detected
as positive (Table 1).
IgG assay evaluation
In the IgG IIFT evaluation, results of the IgG IIFT were
compared to PRNT50 values of V5 (56 days post immunisation).
97 of the 100 sera showed a positive PRNT50 result. 91 of these 97
PRNT50 positive sera (93.8%) were detected as IIFT positive with
titres of up to 1:1000 whereas six PRNT50 positive sera were
detected as negative by IIFT. The PRNT50 titre range of these six
sera was 1:24 to 1:182. Two of these sera were IgG and one
additionally IgM positive in the IIFT at V4, but declined to, for
the IgG IIFT, undetectable levels by V5. All 100 V0 sera and the
three PRNT50 negative sera of V5 were detected as negative by
the IgG IIFT. In summary, the IgG IIFT showed a specificity of
100% (95% CI 96.4–100%), a sensitivity of 93.8% (95% CI 87.2–
97.1%), a positive predictive value of 100% (95% CI 96–100%)
and a negative predictive value of 94.5% (95% CI 88.5–97.5%) in
comparison to the PRNT50 (Table 4). Figure 3 demonstrates the
relation between the PRNT50 and IIFT titres. A certain
distribution is detectable, but the trend line shows a clear increase.
Lastly, the results of the InBios IgG ELISA were compared to
the results of the PRNT50 at V5. Only 6.6% (n=6) of the InBios
ELISA results were in accordance with the positive results of the
PRNT50, whereas 56% (n=51) of the positive PRNT50 results
were not detected by the InBios ELISA. 37.4% (n=34) of all 91
tested samples were equivocal and a diagnosis was not possible.
The geometric mean of the PRNT50 values for the positive
samples was 1:260, for the equivocal samples 1:421 and for the
negative samples it was 1:198.
Table 1. Reactivity of IgM and IgG antibodies directed against JEV in ELISA and IIFT.
anti-JEV IgM anti-JEV IgG
Sera positive by Panbio
ELISA/sera tested
[Panbio Units range]
Sera positive by
InBios ELISA/sera
tested [ISR range]
Sera positive by
Euroimmun IIFT/sera
tested [titre range]
Sera positive by
InBios ELISA/sera
tested [ISR range]
Sera positive by
Euroimmun IIFT/sera
tested [titre range]
PRNT50 positive vaccinees 50/78 (64%) [0.9–55] 56/78 (72%) [1.4–59.9] 51/78 (65%) [0–320] 6/91 (7%) [0.7–12.4] 91/97 (94%) [0–1000]
PRNT50 negative vaccinees nd nd 0/78 (0%) nd 0/78 (0%)
anti-DENV positive patients 1/10 (10%)
+ [2.0–21.3] 5/10 (50%) [3.5–17.8] 3/15 (20%)* [0–32] 17/20 (85%) [1.4–27.1] 20/20 (100%)* [10–1000]
German blood donors nd nd 4/200 (2%) [0–10] nd 8/197 (4%) [0–32]
nd: not done.
ISR: InBios immune status ratio;
+calculation of JE/dengue ratio can be used to determine the presumptive infection;
*incubation on Flavivirus Profile 2 can be used to determine the presumptive infection.
doi:10.1371/journal.pntd.0000883.t001
Table 2. Calculated specificity, sensitivity, positive and
negative predictive values for the anti-JEV IgM IIFT in
comparison to the Panbio Japanese Encephalitis - Dengue
IgM Combo ELISA and PRNT50.
Pre-characterization (Panbio
Japanese Encephalitis - Dengue
IgM Combo ELISA and PRNT50)
n=151 positive negative
Euroimmun anti-JEV IgM
IIFT
positive 43 5
negative 7 96
Specificity 95% (95% CI 88.9–97.9%)
Sensitivity 86% (95% CI 73.8–93.1%)
Positive predictive value 89.6% (95% CI 77.8–95.5%)
Negative predictive value 93.2% (95% CI 86.6–96.7%)
doi:10.1371/journal.pntd.0000883.t002
Table 3. Calculated specificity, sensitivity, positive and
negative predictive values for the anti-JEV IgM IIFT in
comparison to the InBios JE Detect IgM capture ELISA and
PRNT50.
Pre-characterization (InBios
JE Detect IgM capture ELISA
and PRNT50)
n=148 positive negative
Euroimmun anti-JEV IgM IIFT positive 47 0
negative 9 92
Specificity 100% (95% CI 96–100%)
Sensitivity 83.9% (95% CI 72.2–91.3%)
Positive predictive value 100% (95% CI 92.4–100%)
Negative predictive value 91.1% (95% CI 83.9–95.2%)
doi:10.1371/journal.pntd.0000883.t003
Evaluation of JE Diagnostic Test Systems
www.plosntds.org 4 November 2010 | Volume 4 | Issue 11 | e883Analysis of cross-reactive antibodies
The amount of cross-reactive antibodies in the anti-JEV positive
samples against the different flaviviruses detectable by the
Flavivirus Profile 2 IIFT was assessed. Ten JEV IgM IIFT positive
sera from V3, V4 and V5 and twenty JEV IgG IIFT positive sera
from V5 were tested with the Flavivirus Profile 2. In our study
eight of the ten sera showed no cross-reactivity at all, two sera
showed cross-reactivity against yellow fever virus, but in both cases
the anti-JEV response was dominant. Cross-reactive IgG antibod-
ies were detected in 11 of 20 anti-JEV IgG positive sera. However,
again in all sera the anti-JEV response was predominant.
Moreover, a panel of 15 dengue IgM and 20 dengue IgG
positive samples was tested on the Flavivirus Profile 2 to determine
the possibility of differentiation between the cross-reactivity to JEV
or other flaviviruses and DENV specific antibodies. On IgM level
cross-reactivity against other flaviviruses was observed in four of
the 15 sera. Three of these sera showed cross-reactivity against
JEV. In all four samples the dengue IgM titre was higher than the
titre against the other analyzed flaviviruses (three showed a
difference of one and one of three fluorescence intensity stages).
Ten of the DENV IgM positive sera were tested with both IgM
ELISAs. All sera were diagnosed correctly with the Panbio
combined JEV and DENV IgM ELISA as DENV IgM positive.
In contrast the InBios IgM ELISA detected five sera as anti-
JEV positive, four as equivocal and one sample as anti-JEV
negative.
A cross-reactive anti-JEV IgG response was observed with the
Flavivirus Profile 2 IIFT in all 20 DENV positive sera, but in 80%
of the tested sera the anti-DENV IgG response was higher than
the anti-JEV response (60% showed a difference of one and 20%
of two or more fluorescence intensity stages). All 20 dengue IgG
positive sera were tested with the InBios IgG ELISA. 85% of the
sera were detected as anti-JEV IgG positive.
Furthermore, the anti-JEV antibody prevalence in the northern
German population was determined by analyzing a panel of
healthy German blood donors with the anti-JEV IIFT. 2% of the
sera showed a positive result in the anti-JEV IgM IIFT and 4.1%
in the anti-JEV IgG IIFT.
Course of immune reaction after vaccination
The course of the IgG and IgM response after JE vaccination
was analyzed additionally. All PRNT50 positive sera (n=266)
were incubated on both IIFTs. Overall 72.6% (n=193) of these
sera were detected as positive by either the IgM or IgG IIFT. IgM
IIFT titres were generally lower than IgG titres. On V3 18.2%
(n=8) of the PRNT50 positive sera (n=44) were IgG positive and
9.1% (n=4) IgM positive, on V4 the percentage of IgG and IgM
positive was 90.8% (n=89) and 31.6% (n=31), respectively, and
on V5 it was 93.8% (n=91) and 15.5% (n=15).
94% (n=94) of the vaccinated individuals (n=100) developed
within the analyzed time span a measurable IgG response,
whereas only 33% (n=33) developed an IgM response detectable
with the anti-JEV IgM IIFT. Within the group of the IgM positive
sera 94% (n=31) showed detectable IgM levels at V4, whereas on
V5 only 45.5% (n=15) of the individuals were still positive.
Six vaccinees had undetectable IgG titres at all points in time.
Three of these six vaccinees were PRNT50 positive for at least two
points in time, two were slightly PRNT50 positive (up to 1:54) for
at least one point of time and one was PRNT50 negative. All six
vaccinees showed likewise negative IgM IIFT results.
Figure 1. Scatter blot comparing the results of the InBios and the Panbio IgM capture ELISA with the results of the EUROIMMUN
IgM IIFT. To facilitate the readability one IIFT outlier (1:320) was taken out of the diagram. Test values: Panbio IgM capture ELISA results (&), InBios
IgM capture ELISA results (X). Trend line: Panbio IgM capture ELISA results (thin), InBios IgM capture ELISA results (thick).
doi:10.1371/journal.pntd.0000883.g001
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IgM and IgG titres were detectable simultaneously. Only in 9.1%
(n=3) of these vaccinees the IgM reaction was detectable before the
IgG response. The PRNT50 titre range of the sera undetectable in
IgM IIFT was 1:10 to 1:1965 (n=216, geometric mean=133), and
for the sera undetectable in IgG IIFT it was 1:10 to 1:317 (n=77,
geometric mean=52).
In figure 4 some typical courses of IgM and IgG titres in
comparison to the PRNT50 titre are demonstrated. The course of
the immune response of vaccinee no. 1 shows a clear decrease in
the PRNT50 as well as in the IgG titre. As in most of the analyzed
samples no IgM antibodies were detected in vaccinee no. 1. In
vaccinee no. 2 both antibody classes were found. IgM is detectable
before IgG as seen in 9.1% (n=3) of the IgM positive vaccinees.
Although the PRNT50 titre is increasing, the IgM and/or IgG
titre measured by IIFT decreases. This effect is also seen in
vaccinee no. 4 and found in 7% (n=7) of all the vaccinees.
In 36.4% (n=12) of all IgM positive vaccinees the IgM and IgG
titres descended simultaneously, as in vaccinee no. 3. In this case
the PRNT50 titre displayed the same course as the IgM and IgG
titre. A simultaneous course of all measurable titres was also seen
in 40% (n=40) of the analyzed vaccinees, in 26% (n=26) of these
the PRNT50, IgM and/or IgG titres descended simultaneously
and in 14% (n=14) all measurable titres ascended simultaneously
over time. Generally, in 66% (n=66) of the vaccinees the
PRNT50 titre declined towards the end of the study. In vaccinees
no. 4 and 5, as in 30.3% (n=10) of all IgM positive vaccinees, a
decline of the IgM titre was observed while the IgG titre was
constant until the last analysis. In 12.1% (n=4) of all IgM positive
vaccinees, as also seen in vaccinee no. 6, the IgM titre declined
while the IgG titre increased over the analyzed time span.
Discussion
The performance of the new anti-JEV IIFT was compared to
two different IgM-capture ELISAs and the PRNT50.
Overall, the anti-JEV IgM IIFT showed a performance com-
parable to the IgM-capture ELISAs. The difference in specificity
of the IIFT found in comparison to the Panbio and the concordant
results compared to the InBios assay might be due to a difference
in the sensitivity of the respective ELISAs. The Panbio ELISA
revealed in the published evaluation study [22] with 89.3% a lower
sensitivity than the InBios ELISA with 99.2%.
Figure 2. Scatter blot comparing the results of the PRNT50 with the results of both IgM ELISAs. Test values: Panbio IgM ELISA (X), InBios
IgM ELISA (&). Trend line: Panbio IgM ELISA (thin), InBios IgM ELISA (thick).
doi:10.1371/journal.pntd.0000883.g002
Table 4. Calculated specificity, sensitivity, positive and
negative predictive values for the anti-JEV IgG IIFT in
comparison to the PRNT50.
Pre-characterization
(PRNT50)
n=200 positive negative
Euroimmun anti-JEV IgG IIFT positive 91 0
negative 6 103
Specificity 100% (95% CI 96.4–100%)
Sensitivity 93.8% (95% CI 87.2–97.1%)
Positive predictive value 100% (95% CI 96–100%)
Negative predictive value 94.5% (95% CI 88.5–97.5%)
doi:10.1371/journal.pntd.0000883.t004
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sensitive than the IgM IIFT. This phenomenon has been detected
in several IIFT evaluation studies and might be explained by
different sample amounts, different antigens used for the assays
and differences in the presentation of the antigen. Both ELISAs
relied on recombinant antigens, whereas in the IIFT complete
virus was used. However, similar numbers of PRNT50 positive
samples have been detected as positive by all three methods. Thus,
the IgM IIFT represents another diagnostic method which is rapid
to perform and especially suitable for small serum numbers. An
additional advantage of the IIFT is the possibility to identify and
exclude unspecific reactive sera by recognizing the unspecific
staining of the non-infected control cells.
The anti-JEV IgG IIFT revealed 56 days after vaccination a
sensitivity comparable to the PRNT50, but it is much faster and
easier to perform than the time-consuming PRNT50 as the
performance of the IIFT takes only 1.5 hours. In contrast, the
InBios IgG ELISA revealed in this study an inadequate detection
of PRNT50 positive samples and is therefore not suitable to
determine the antibody response after JEV vaccination.
Although the actual protective immunity can only be deter-
mined by the neutralization assay, the IgG IIFT offers a possible
alternative to assess the anti-JEV IgG titre after vaccination. This
might for example be a valuable tool for a rapid diagnosis of the
immune status in travellers. Nevertheless, the limitation of the use
of the IIFT in assessing the antibody response after JE vaccination
lies in the presence of flavivirus cross-reactive antibodies from
previous infections. Therefore, the intensity of the detection of
cross-reactive antibodies in different serum panels was studied.
The Flavivirus Profile 2 was used to determine the level of cross-
reactivity detected in IIFT in the JE-vaccinated persons. In eight of
the ten sera no cross-reactivity at the IgM level was found. Similar
results have been described in the literature [17]. TheIgGresponses
however showed a high cross-reactivity, although altogether the
reactivity of IgM and IgG antibodies with the other flavivirus IIFT
substrates was generally lower than with the JEV substrate.
The results of the DENV positive panel tested in all three assays
revealed that even the use of a recombinant antigen as found in
the Panbio and InBios ELISA cannot prevent cross-reactivity. The
high cross-reactivity shown by the Inbios IgM ELISA was in
accordance with the results published previously [22], in which the
Inbios IgM ELISA showed a specificity of 56.1%. The results of
the three assays demonstrate that in areas where both viruses are
endemic it is advisable to test for specific antibodies against at least
JEV and DENV simultaneously [16], as performed in the Panbio
assay and the Flavivirus Profile 2.
Nevertheless, to differentiate between a specific and a cross-
reactive immune response in the case of an acute infection a
fourfold increase in the titre of a consecutive serum should be
demonstrated. However, a single IgM positive result can also be
confirmed by other techniques such as PRNT. Additionally, NS1
antigen detection could be a valuable tool for the early diagnosis of
Japanese encephalitis virus infections. In dengue infection e.g. NS1
is detectable very early, before IgM is produced and up to 9 days
after the beginning of symptoms. The overall diagnostic sensitivity
in early stages of the dengue disease was increased by the
combination of NS1 and IgM detection [24].
The detection of anti-JEV IgM and IgG antibodies in the
northern German population could be explained by cross-reactive
antibodies against other flaviviruses, for example due to vaccina-
tion against tick-borne encephalitis or yellow fever. Therefore, also
in areas without JEV and DENV occurrence it should be taken
into account that cross-reactive antibodies against other flavivi-
ruses can alter the serological results. Additionally, in patients with
Figure 3. Scatter blot comparing the results of the PRNT50 with the results of the EUROIMMUN IIFT. Test values: IgM (X), IgG (&).
Trend line: IgM (thick), IgG (thin).
doi:10.1371/journal.pntd.0000883.g003
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be considered.
Furthermore, the course of specific antibodies after JE vaccina-
tion detectable by IIFT was determined. Altogether only 33% of
the vaccinated persons established an IgM response detectable in
IIFT. Therefore, if the detection of the anti-JEV titre after
vaccination is needed, it might be advisable to test for IgG rather
than for IgM. Since on day 28 after vaccination the IgG response
was at 18% still rather low, the best time to determine the IgG titre
was from 35 days after vaccination onwards.
It is expected that in sera from acutely infected persons the
fraction of sera detected as IgM and also IgG positive in the IIFT
will be higher, as their serological immune response is stronger.
But this has to be evaluated with a panel of sera from persons from
endemic areas infected naturally with JEV.
Overall the new Euroimmun JEV IIFT showed comparable
results to the commonly used commercial IgM capture ELISAs and
the ‘‘gold standard’’ in flavivirus diagnosis, the PRNT50. It is a
valuabletoolforanalyzingthe immuneresponseaftervaccinationin
travellers and people resident in endemic areas and it might prove
useful for the diagnosis of acutely infected persons.
Supporting Information
Checklist S1 STARD Checklist
Found at: doi:10.1371/journal.pntd.0000883.s001 (0.05 MB DOC)
Figure 4. Exemplary courses of serological IgM, IgG and neutralizing antibody titres, determined by the EUROIMMUN IgM and IgG
IIFT and the PRNT50. Test values: IgM IIFT titres (striped boxes), IgG IIFT titres (filled boxes), PRNT50 titres (line).
doi:10.1371/journal.pntd.0000883.g004
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